Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 6.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 235,386 shares of the company’s stock after buying an additional 14,324 shares during the period. JPMorgan Chase & Co. owned about 0.16% of Denali Therapeutics worth $6,857,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. CWM LLC grew its stake in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares in the last quarter. Quest Partners LLC bought a new stake in Denali Therapeutics in the third quarter worth approximately $73,000. Assetmark Inc. grew its position in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Denali Therapeutics during the 2nd quarter valued at $194,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $21.50 on Thursday. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33. The stock has a market cap of $3.09 billion, a PE ratio of -7.79 and a beta of 1.39. The firm has a 50-day simple moving average of $23.48 and a 200 day simple moving average of $24.77.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the company posted ($0.72) earnings per share. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares of the company’s stock, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock worth $2,576,982 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on DNLI shares. Robert W. Baird assumed coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price objective for the company. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Monday, December 16th. HC Wainwright decreased their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.